dr. mirza on impact of niraparib in ovarian cancer
Published 7 years ago • 123 plays • Length 0:57Download video MP4
Download video MP3
Similar videos
-
0:52
dr. mirza on safety profile of niraparib/bevacizumab in recurrent ovarian cancer
-
2:18
dr. mirza on efficacy of niraparib/bevacizumab combo in recurrent ovarian cancer
-
0:53
dr. mirza on the impact of parp inhibitors in ovarian cancer
-
1:30
dr. mirza on niraparib efficacy across ovarian cancer subgroups
-
1:41
dr. mirza on niraparib plus bevacizumab combo in ovarian cancer
-
2:26
dr. mirza discusses niraparib dose modifications for ovarian cancer patients with low body weight
-
1:35
dr. mirza on the phase iii nova trial in ovarian cancer
-
2:18
dr. mirza on final data of the nsgo-avanova2/engot-ov24 trial in ovarian cancer
-
1:30
dr. mirza on the evolving treatment landscape in recurrent ovarian cancer
-
0:56
dr. mirza on the implications of the nsgo-avanova2/engot-ov24 trial in ovarian cancer
-
8:29
esmo 2019: dr. mirza on important trials with parp inhibitors in ovarian cancer
-
2:11
dr. mirza on the rationale for the avanova trial in recurrent ovarian cancer
-
3:14
personalized dosing of niraparib in ovarian cancer
-
2:35
clinical use of niraparib in ovarian cancer
-
9:25
results from the engot-ov16/nova trial: efficacy and safety of niraparib in ovarian cancer
-
2:55
results of engot-ov16/nova phase iii trial of niraparib in platinum-sensitive ovarian cancer
-
3:08
ovarian cancer: optimizing treatment with niraparib
-
6:57
niraparib maintenance for recurrent ovarian cancer
-
6:31
prima: frontline niraparib maintenance therapy in ovarian cancer